Stonepine Capital Management LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Stonepine Capital Management LLC acquired a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 30,000 shares of the company’s stock, valued at approximately $306,000. Stonepine Capital Management LLC owned about 0.08% of iTeos Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ITOS. nVerses Capital LLC grew its holdings in shares of iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after acquiring an additional 2,646 shares in the last quarter. Quest Partners LLC lifted its position in shares of iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares in the last quarter. US Bancorp DE lifted its position in shares of iTeos Therapeutics by 206.0% in the third quarter. US Bancorp DE now owns 12,076 shares of the company’s stock worth $123,000 after buying an additional 8,129 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of iTeos Therapeutics in the third quarter worth about $126,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Analysts Set New Price Targets

ITOS has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research report on Tuesday, November 12th. Wells Fargo & Company began coverage on iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. cut their target price on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Friday, November 15th.

iTeos Therapeutics Stock Performance

Shares of ITOS traded up $0.27 during midday trading on Wednesday, hitting $8.46. 37,808 shares of the company’s stock traded hands, compared to its average volume of 444,008. iTeos Therapeutics, Inc. has a 1 year low of $7.54 and a 1 year high of $18.75. The firm’s fifty day moving average is $9.29 and its 200-day moving average is $13.77.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. Equities research analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall acquired 5,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 12.50% of the company’s stock.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.